Amatuximab and novel agents targeting mesothelin for solid tumors

References

• ChangKPaiLHBatraJKPastanIWillinghamMCCharacterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesotheliumCancer Res19925211811861727378
   PubMedGoogle Scholar
• ChangKPastanIMolecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancersProc Natl Acad Sci U S A19969311361408552591
   PubMed Web of Science ®Google Scholar
• SteinbachDOndaMVoigtAMesothelin, a possible target for immunotherapy, is expressed in primary AML cellsEur J Haematol200779428128617803679
   PubMed Web of Science ®Google Scholar
• YuLFengMKimHMesothelin as a potential therapeutic target in human cholangiocarcinomaJ Cancer20101114114920922056
   PubMedGoogle Scholar
• HoMOndaMWangQCHassanRPastanILivelyMOMesothelin is shed from tumor cellsCancer Epidemiol Biomarkers Prev2006159175116985043
   PubMedGoogle Scholar
• OrdóñezNGWhat are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and updateHum Pathol200738111617056092
   PubMedGoogle Scholar
• BernabeiRGambassiGLapaneKCharacteristics of the SAGE database: a new resource for research on outcomes in long-term care. SAGE (Systematic Assessment of Geriatric drug use via Epidemiology) Study GroupJ Gerontol A Biol Sci Med Sci1999541M25M3310026659
   PubMedGoogle Scholar
• OrdóñezNGApplication of mesothelin immunostaining in tumor diagnosisAm J Surg Pathol200327111418142814576474
   PubMed Web of Science ®Google Scholar
• RobinsonBWCreaneyJLakeRMesothelin-family proteins and diagnosis of mesotheliomaLancet200336293961612161614630441
   PubMed Web of Science ®Google Scholar
• RumpAMorikawaYTanakaMBinding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesionJ Biol Chem2004279109190919814676194
   PubMed Web of Science ®Google Scholar
• ChengWFHuangCYChangMCHigh mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinomaBr J Cancer200910071144115319293794
   PubMed Web of Science ®Google Scholar
• UeharaNMatsuokaYTsuburaAMesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cellsMol Cancer Res20086218619318245228
   PubMed Web of Science ®Google Scholar
• KanekoOGongLZhangJA binding domain on mesothelin for CA125/MUC16J Biol Chem200928463739374919075018
   PubMed Web of Science ®Google Scholar
• BharadwajUMarin-MullerCLiMChenCYaoQMesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpressionMol Cancer20113110106
   Google Scholar
• ChenSHHungWCWangPPaulCKonstantopoulosKMesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activationSci Rep20133187023694968
   PubMed Web of Science ®Google Scholar
• MorelloASadelainMAdusumilliPSMesothelin-targeted CARs: driving t cells to solid tumorsCancer Discov20166213314626503962
   PubMed Web of Science ®Google Scholar
• FesnakADJuneCHLevineBLEngineered T cells: the promise and challenges of cancer immunotherapyNat Rev Cancer201616956658127550819
   PubMed Web of Science ®Google Scholar
• DeVitaVTJrLawrenceTSRosembergSACancer: Principles & Practice of Oncology10th edUSAWolters Kluwer Health Inc.2015
   Google Scholar
• PastanIHassanRDiscovery of mesothelin and exploiting it as a target for immunotherapyCancer Res201474112907291224824231
   PubMed Web of Science ®Google Scholar
• HassanRRemaleyATSampsonMLDetection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancerClin Cancer Res200612244745316428485
   PubMed Web of Science ®Google Scholar
• RarecareNet: Information Network on rare Cancers [homepage on the Internet]BrusselsDirectorate for public health and risk assessment Available from: http://www.rarecarenet.eu/rarecarenet/index.php/cancerlistAccessed April 18, 2017
   Google Scholar
• Cancer A–Z, Key-statistics – What Are the Key Statistics about Malignant Mesothelioma? [homepage on the Internet]New YorkAmerican Cancer Society Available from: https://www.cancer.org/cancer/malignant-mesothelioma/about/key-statistics.htmlAccessed April 28, 2017
   Google Scholar
• TetaMJMinkPJLauESceurmanBKFosterEDUS mesothelioma patterns 1973–2002: indicators of change and insights into background ratesEur J Cancer Prev200817652553418941374
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease Cancer CollaborationFitzmauriceCAllenCBarberRMGlobal, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease StudyJAMA Oncol20173452454827918777
   PubMed Web of Science ®Google Scholar
• YangHBocchettaMKroczynskaBTNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesisProc Natl Acad Sci U S A200610327103971040216798876
   PubMed Web of Science ®Google Scholar
• MagnaniC1FerranteDBarone-AdesiFCancer risk after cessation of asbestos exposure: a cohort study of Italian asbestos cement workersOccup Environ Med200865316417017704197
   PubMed Web of Science ®Google Scholar
• GoodmanJENascarellaMAValbergPAIonizing radiation: a risk factor for mesoteliomaCancer Causes Control2009201237125419444627
   PubMed Web of Science ®Google Scholar
• AscoliVRomeoECarnovale ScalzoCFamilial malignant mesotelioma: a population-based study in central Italy [1980–2012]Cancer Epidemiol20143827327824684899
   PubMed Web of Science ®Google Scholar
• NovelloSPintoCTorriVThe Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendationsCrit Rev Oncol Hematol201610492027286698
   PubMed Web of Science ®Google Scholar
• ChiaPLRussellPAScottAMJohnTTargeting the vasculature: anti-angiogenic agents for malignant mesotheliomaExpert Rev Anticancer Ther201616121235124527696931
   PubMed Web of Science ®Google Scholar
• StahelRAWederWFelley-BoscoESearching for targets for the systemic therapy of mesotheliomaAnn Oncol20152681649166025722383
   PubMedGoogle Scholar
• KatafygiotisPGiaginisCPatsourisETheocharisSHistone deacetylase inhibitors as potential therapeutic agents for the treatment of malignant mesotheliomaAnticancer Agents Med Chem201313347648222931420
   PubMedGoogle Scholar
• O’HaraMStashwickCHaasARTanyiJLMesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapyImmunotherapy20168444946026973126
   PubMedGoogle Scholar
• HassanRThomasAAlewineCLeDTJaffeeEMPastanIMesothelin immunotherapy for cancer: ready for prime time?J Clin Oncol201634344171417927863199
   PubMed Web of Science ®Google Scholar
• The Human Protein Atlas [home page on the Internet] Available from: www.proteinatlas.orgAccessed June 10, 2017
   Google Scholar
• ArganiPIacobuzio-DonahueCRyuBMesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)Clin Cancer Res20017123862386811751476
   PubMed Web of Science ®Google Scholar
• HassanRLaszikZGLernerMRaffeldMPostierRBrackettDMesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitisAm J Clin Pathol2005124683884516416732
   PubMed Web of Science ®Google Scholar
• ZervosEAgleSFreistaedterAGJonesGJRoperRLMurine mesothelin: characterization, expression, and inhibition of tumor growth in a murine model of pancreatic cancerJ Exp Clin Cancer Res2016353926931187
   PubMed Web of Science ®Google Scholar
• KolivasERudloffMPoruchynskyMMesothelin-targeted immunotoxin RG7797 has synergistic anti-tumor activity when combined with taxanesOncotarget2017869189919927999204
   PubMedGoogle Scholar
• HanaokaTHasegawaKKatoTCorrelation between tumor mesothelin expression and serum mesothelin in patients with epithelial ovarian carcinoma: a potential noninvasive biomarker for mesothelin-targeted therapyMol Diagn Ther201721218719828160193
   PubMed Web of Science ®Google Scholar
• van ScheltingaAOgasawaraAPachecoGPreclinical efficacy of antibody-drug conjugate targeting mesothelin correlates with quantitative 89Zr-immunoPETMol Cancer Ther201716113414227760836
   PubMedGoogle Scholar
• KobayashiKSasakiTTakenakaFA novel PET imaging using 64Cu-labeled monoclonal antibody against mesothelin commonly expressed on cancer cellsJ Immunol Res2015201526817225883990
   PubMedGoogle Scholar
• LambertsLEMenke-van der Houven van OordtCWter WeeleEJImmunoPET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody-drug conjugate treatmentClin Cancer Res20162271642165226589435
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov [homepage on the Internet]Registry and results database of publicly and privately supported clinical studies of human participants conducted around the world Available from: http://www.clinicaltrials.gov/Accessed August 10, 2017
   Google Scholar
• LiRYXianRRZioberAMesothelin expression is associated with poor outcomes in breast cancerBreast Cancer Res Treat2014147367568425193277
   PubMed Web of Science ®Google Scholar
• BayogluIVKucukzeybekBBKucukzeybekYPrognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancersBiomed Pharmacother20157019019525776500
   PubMedGoogle Scholar
• ParinyanitikulNBlumenscheinGRWuYMesothelin expression and survival outcomes in triple receptor negative breast cancerClinical Breast Cancer201313537838423810431
   PubMedGoogle Scholar
• OrdonezNGApplication of mesothelin immunostaining in tumor diagnosisAm J Surg Pathol200327111418142814576474
   PubMed Web of Science ®Google Scholar
• MiettinenMSarlomo-RikalaMExpression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleuraAm J Surg Pathol200327215015812548160
   PubMed Web of Science ®Google Scholar
• HoMBeraTKWillinghamMCMesothelin expression in human lung cancerClin Cancer Res20071351571157517332303
   PubMed Web of Science ®Google Scholar
• MahlonDJFranVO’ConnelMJMesothelin expression in the leptomeninges and meningiomasJ Histochem Cytochem200856657958518347077
   PubMedGoogle Scholar
• ThomasAChenYBermanAExpression of mesothelin in thymic carcinoma and its potential therapeutic significanceLung Cancer201610110411027794397
   PubMedGoogle Scholar
• InagumaSwangZlasotaJComprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesotheliomaOncotarget2017816267442675428460459
   PubMedGoogle Scholar
• TomoakiIKazunoriKMasaakiAERC/mesothelin is espresse in human gastric cancer tissues and cell linesOncol Rep2014311273324146039
   PubMedGoogle Scholar
• HanSHJooMKimHChangSMesothelin expression in gastric adenocarcinoma and its relation to clinical outcomesJ Pathol Transl Med201751212212828196410
   PubMed Web of Science ®Google Scholar
• ChowdhuryPSVinerJLBeersRPastanIIsolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activityProc Natl Acad Sci U S A1998956696749435250
   PubMed Web of Science ®Google Scholar
• HassanREbelWRouthierELPreclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelinCancer Immun200719720
   Google Scholar
• MuminovaZEStrongTVShawDRCharacterization of human mesothelin transcripts in ovarian and pancreatic cancerBMC Cancer200412419
   Google Scholar
• MorenoMMolBMvon Mensdorff-PouillySToll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC)Cancer Lett20082721707618684557
   PubMedGoogle Scholar
• FengYXiaoXZhuZA novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by ADCCMol Cancer Ther2009851113111819417159
   PubMedGoogle Scholar
• GubbelsJBelisleJOndaMMesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumorsMol Cancer200655017067392
   PubMed Web of Science ®Google Scholar
• HassanRCohenSJPhillipsMPhase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancersClin Cancer Res201016246132613821037025
   PubMed Web of Science ®Google Scholar
• GuptaAHusseinZHassanRWustnerJMaltzmanJDWallinBAPopulation pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selectionCancer Chemother Pharmacol201677473374326898299
   PubMed Web of Science ®Google Scholar
• FujisakaYKurataTTanakaKPhase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumorsInvest New Drugs201533238038825502863
   PubMed Web of Science ®Google Scholar
• LindenbergLThomasAAdlerSSafety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imagingOncotarget2015664496450425756664
   PubMedGoogle Scholar
• MorphotekA study of MORAb-009 in subjects with pancreatic cancer, mesothelioma, or certain types of ovarian or lung cancer Available from: https://clinicaltrials.gov/ct2/show/NCT00325494. NLM identifier: NCT00325494Accessed May 24, 2017
   Google Scholar
• Eisai Co. Ltd., Eisai IncA study of MORAb-009 in patients with solid tumors Available from: https://clinicaltrials.gov/ct2/show/NCT01018784. NLM identifier: NCT01018784Accessed May 24, 2017
   Google Scholar
• MorphotekAn efficacy study of MORAb-009 (amatuximab) in subjects with pleural mesothelioma Available from: https://clinicaltrials.gov/ct2/show/NCT00738582. NLM Identifier: NCT00738582Accessed May 24, 2017
   Google Scholar
• HassanRKindlerHLJahanTPhase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesotheliomaClin Cancer Res201420235927593625231400
   PubMed Web of Science ®Google Scholar
• MorphotekAn efficacy study of MORAb-009 in subjects with pancreatic cancer Available from: https://clinicaltrials.gov/ct2/show/NCT00570713. NLM identifier: NCT00570713Accessed May 24, 2017
   Google Scholar
• MorphotekStudy of the safety and efficacy of amatuximab in combination with pemetrexed and cisplatin in subjects with unresectable malignant pleural mesothelioma (MPM) Available from: https://clini-caltrials.gov/ct2/show/NCT02357147. NLM identifier: NCT02357147Accessed May 24, 2017
   Google Scholar
• MorphotekA single-dose pilot study of radiolabeled amatuximab (MORAb-009) in mesothelin over-expressing cancers Available from: https://clinicaltrials.gov/ct2/show/NCT01521325. NLM identifier: NCT01521325Accessed May 24, 2017
   Google Scholar
• National Cancer Institute (NCI)National Institutes of Health Clinical Center (CC)Amatuximab for high mesothelin cancers Available from: https://clinicaltrials.gov/ct2/show/NCT01413451. NLM identifier: NCT01413451Accessed May 24, 2017
   Google Scholar
• KreitmanRJHassanRFitzgeraldDJPastanIPhase 1 trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1PClin Cancer Res2009155274527919671873
   PubMed Web of Science ®Google Scholar
• National Cancer Institute (NCI)National Institutes of Health Clinical Center (CC)SS1P and pentostatin plus cyclophosphamide for mesothelioma Available from: https://clinicaltrials.gov/ct2/show/NCT01362790. NLM identifier: NCT01362790Accessed June 6, 2017
   Google Scholar
• National Cancer Institute (NCI)National Institutes of Health Clinical Center (CC)A phase I trial of SS1 (dsFv) PE38 with paclitaxel, carboplatin, and bevacizumab in subjects with unresectable non-small cell lung adenocarcinoma Available from: https://clinicaltrials.gov/ct2/show/NCT01051934. NLM identifier: NCT01051934Accessed June 6, 2017
   Google Scholar
• National Cancer Institute (NCI)National Institutes of Health Clinical Center (CC)Mesothelin-targeted immunotoxin LMB-100 in people with malignant mesothelioma Available from: https://clinicaltrials.gov/ct2/show/NCT02798536. NLM identifier: NCT02798536Accessed June 6, 2017
   Google Scholar
• National Cancer Institute (NCI)National Institutes of Health Clinical Center (CC)Mesothelin-targeted immunotoxin LMB-100 alone or in combination with nab-paclitaxel in people with previously treated metastatic and/or locally advanced pancreatic ductal adenocarcinoma and mesothelin expressing solid tumors Available from: https://clini-caltrials.gov/ct2/show/NCT02810418. NLM identifier: NCT02810418Accessed June 6, 2017
   Google Scholar
• ZhangJKhannaSJiangQEfficacy of anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against mesothelioma patient-derived xenografts and mesothelin as a biomarker of tumor responseClin Cancer Res20172361564157427635089
   PubMed Web of Science ®Google Scholar
• BrockstedtDGGiedlinMALeongMLListeria-based cancer vaccines that segregate immunogenicity from toxicityProc Natl Acad Sci U S A2004101138321383715365184
   PubMed Web of Science ®Google Scholar
• LeDTWang-GillamAPicozziVSafety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancerJ Clin Oncol2015331325133325584002
   PubMed Web of Science ®Google Scholar
• Aduro Biotech, IncSafety and efficacy of combination listeria/GVAX pancreas vaccine in the pancreatic cancer setting Available from: https://clinicaltrials.gov/ct2/show/NCT02004262. NLM identifier: NCT02004262Accessed June 6, 2017
   Google Scholar
• Sidney Kimmel Comprehensive Cancer CenterBristol-Myers SquibbStand Up to CancerAduro BioTechAmerican Association for Cancer ResearchGVAX pancreas vaccine (with CY) and CRS-207 with or without nivolumab Available from: https://clinicaltrials.gov/ct2/show/NCT02243371. NLM identifier: NCT02243371Accessed June 10, 2017
   Google Scholar
• Sidney Kimmel Comprehensive Cancer CenterEpacadostat, pembrolizumab, and CRS-207, with or without CY/GVAX pancreas in patients with metastatic pancreas cancer Available from: https://clinicaltrials.gov/ct2/show/NCT03006302. NLM identifier: NCT03006302Accessed June 10, 2017
   Google Scholar
• Aduro Biotech, Inc.Incyte CorporationSafety and efficacy of CRS-207 with epacadostat in platinum resistant ovarian, fallopian or peritoneal cancer Available from: https://clinicaltrials.gov/ct2/show/NCT02575807. NLM identifier: NCT02575807Accessed June 10, 2017
   Google Scholar
• Aduro Biotech, IncSafety and efficacy of listeria in combination with chemotherapy as front-line treatment for malignant pleural mesothelioma Available from: https://clinicaltrials.gov/ct2/show/NCT01675765. NLM identifier: NCT01675765Accessed June 10, 2017
   Google Scholar
• GolfierSKopitzCKahnertAAnetumab ratvansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effectMol Cancer Ther20141361537154824714131
   PubMed Web of Science ®Google Scholar
• Bayer-Immunogen and MorphoSysPhase II anetumab ratvansine as 2nd line treatment for malignant pleural mesothelioma (MPM) Available from: https://clinicaltrials.gov/ct2/show/NCT2610140. NLM identifier: NCT02610140Accessed August 14, 2017
   Google Scholar
• Howard HochsterBayerYale UniversityPhase II anetumab ravtansine in pre-treated mesothelin-expressing pancreatic cancer Available from: https://clinicaltrials.gov/ct2/show/NCT03023722. NLM identifier: NCT03023722Accessed June 10, 2017
   Google Scholar
• National Cancer Institute (NCI)National Institutes of Health Clinical Center (CC)Anti-mesothelin antibody drug conjugate anetumab ravtansine for mesothelin expressing lung adenocarcinoma Available from: https://clinicaltrials.gov/ct2/show/NCT02839681. NLM identi-fier: NCT02839681Accessed June 10, 2017
   Google Scholar
• National Cancer Institute (NCI)Pembrolizumab with or without anetumab ravtansine in treating patients with mesothelin-positive pleural mesothelioma Available from: https://clinicaltrials.gov/ct2/show/NCT03126630. NLM identifier: NCT03126630Accessed June 10, 2017
   Google Scholar
• FranciscoJACervenyCGMeyerDLcAC10-vcMMAE, an anti CD30 monomethyl auristatin E conjugate with potent and selective antitumor activityBlood20031021458146512714494
   PubMed Web of Science ®Google Scholar
• ScalesSJGuptaNPachecoGAn antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma modelsMol Cancer Ther2014132630264025249555
   PubMed Web of Science ®Google Scholar
• Genentech, IncA study of DMOT4039A in participants with unresectable pancreatic or platinum-resistant ovarian cancer Available from: https://clinicaltrials.gov/ct2/show/NCT01469793. NLM identifier: NCT001469793Accessed July 27, 2017
   Google Scholar
• WeekesCDLambertsLEBoradMJPhase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancerMol Cancer Ther201615343944726823490
   PubMed Web of Science ®Google Scholar
• ZhaoXYSubramanyamBSarapaNGolfierSDinterHNovel antibody therapeutics targeting mesothelin in solid tumorsClin Cancer Drugs201632768627853672
   PubMedGoogle Scholar
• Bristol-Myers SquibbA study of BMS-986148 in patients with select advanced solid tumors Available from: https://clinicaltrials.gov/ct2/show/NCT02341625. NLM identifier: NCT02341625Accessed July 27, 2017
   Google Scholar
• Bristol-Myers SquibbPhase 1 study of mesothelin-ADC Available from: https://clinicaltrials.gov/ct2/show/NCT02884726. NLM identifier: NCT02884726Accessed July 27, 2017
   Google Scholar
• Couzin-FrankelJBreakthrough of the yearScience201334261651432143324357284
   PubMed Web of Science ®Google Scholar
• FesnakADJuneCHLevineBLEngineered T cells: the promise and challenges of cancer immunotherapyNat Rev Cancer201616956658127550819
   PubMed Web of Science ®Google Scholar
• ShiHSunMLiuLWangZChimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospectsMol Cancer20141321925241075
   PubMed Web of Science ®Google Scholar
• WangZGuoYHanWCurrent status and perspectives of chimeric antigen receptor modified T cells for cancer treatmentProtein Cell2017 Epub May 2
   Google Scholar
• SadelainMCAR therapy: the CD19 paradigmJ Clin Invest201512593392340026325036
   PubMed Web of Science ®Google Scholar
• SunHVaynblatAPassHIDiagnosis and prognosis – review of biomarkers for mesotheliomaAnn Transl Med201751124428706912
   PubMedGoogle Scholar
• LevinPADowellJESpotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to dateOnco Targets Ther2017102057206628435296
   PubMed Web of Science ®Google Scholar
• TangZQianMHoMThe role of mesothelin in tumor progression and targeted therapyAnticancer Agents Med Chem201313227628022721387
   PubMed Web of Science ®Google Scholar
• MancusoMNealJWNovel systemic therapy against malignant pleural mesotheliomaTransl Lung Cancer Res20176329531428713675
   PubMedGoogle Scholar
• KreitmanRJStetler-StevensonMMarguliesIPhase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemiaJ Clin Oncol200927182983299019414673
   PubMed Web of Science ®Google Scholar
• KreitmanRJHassanRFitzgeraldDJPastanIPhase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1PClin Cancer Res2009155274527919671873
   PubMed Web of Science ®Google Scholar
• PoonKAFlagellaKBeyerJPreclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cyto-toxic component retained with improved tolerabilityToxicol Appl Pharmacol2013273229831324035823
   PubMed Web of Science ®Google Scholar
• LiDPoonKAYuSFDCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphomaMol Cancer Ther20131271255126523598530
   PubMed Web of Science ®Google Scholar
• CreaneyJRobinsonBWSMalignant mesothelioma biomarkers. From discovery to use in clinical practice for diagnosis, monitoring, screening and treatmentChest2017152114314928007619
   PubMed Web of Science ®Google Scholar
• HassanRWuCBrechbielMWMarguliesIKreitmanRJPastanI111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelinInt J Cancer1999805595639935157
   PubMedGoogle Scholar
• ShinISLeeSMKimHSEffect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibodyNucl Med Biol2011381119112721741258
   PubMed Web of Science ®Google Scholar
• MisriRSaatchiKNgSSKumarUHafeliUOEvaluation of 111In labeled antibodies for SPECT imaging of mesothelin expressing tumorsNucl Med Biol20113888589621843785
   PubMedGoogle Scholar
• YoshidaCSogawaCTsujiABDevelopment of positron emission tomography imaging by 64Cu-labeled fab for detecting ERC/mesothelin in a mesothelioma mouse modelNucl Med Commun20103138038820072072
   PubMedGoogle Scholar
• University Medical Center Groningen89Zr-MMOT PET imaging in pancreatic and ovarian cancer patients (MMOT) Available from: https://clinicaltrials.gov/ct2/show/NCT01832116. NLM identifier: NCT01832116Accessed July 31, 2017
   Google Scholar